Cantrixil + chemotherapy

**Cantrixil + chemotherapy** refers to the combination of Cantrixil (TRX-E-002-1), a third-generation benzopyran molecule administered intraperitoneally, used together with standard intravenous cytotoxic chemotherapy agents for the treatment of advanced, recurrent, or persistent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Cantrixil is designed to target both chemotherapy-sensitive and chemotherapy-resistant ovarian cancer cells, including cancer stem cells, by inducing apoptosis and sensitizing tumor cells to chemotherapy. In clinical trials, Cantrixil was first administered as monotherapy to establish safety and dosage, followed by combination therapy with standard chemotherapy agents (such as cisplatin, carboplatin, paclitaxel, or others chosen by the treating physician) to assess safety, tolerability, and potential synergistic effects. The mechanism of action of Cantrixil is under further investigation, but it has shown in vitro and in vivo activity against chemoresistant stem cells and tumor-initiating cells. Developed by Kazia Therapeutics and later licensed to Oasmia Pharmaceutical (now Vivesto).

Brand names

Cantrixil + chemotherapy

Other names

TRX-E-002-1 + chemotherapyCantrixil in combination with chemotherapy